Qiagen Inks HPV Screening Deal with China's KingMed Diagnostics | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen has signed a co-marketing deal in China with KingMed Diagnostics aimed at expanding access to its digene HPV test.

KingMed is China's largest independent laboratory network, according to Qiagen, and under the agreement will serve as a centralized lab. This will allow smaller hospitals and those in less-populated areas to offer the HPV test and send samples to KingMed for processing and analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.